Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection

Karin Stettler(Vir Biotechnology (Switzerland)), Martina Beltramello(Vir Biotechnology (Switzerland)), Diego A. Espinosa(University of California, Berkeley), Victoria Graham(Public Health England), Antonino Cassotta(ETH Zurich), Siro Bianchi(Vir Biotechnology (Switzerland)), Fabrizia Vanzetta(Vir Biotechnology (Switzerland)), Andrea Minola(Vir Biotechnology (Switzerland)), Stefano Jaconi(Vir Biotechnology (Switzerland)), Federico Mele(Università della Svizzera italiana), Mathilde Foglierini(Università della Svizzera italiana), Mattia Pedotti(Università della Svizzera italiana), Luca Simonelli(Università della Svizzera italiana), Stuart Dowall(Public Health England), Barry Atkinson(Public Health England), Elena Percivalle(Istituti di Ricovero e Cura a Carattere Scientifico), Cameron P. Simmons(Nuffield Orthopaedic Centre), Luca Varani(Università della Svizzera italiana), Johannes Blum(Swiss Tropical and Public Health Institute), Fausto Baldanti(Istituti di Ricovero e Cura a Carattere Scientifico), Elisabetta Cameroni(Vir Biotechnology (Switzerland)), Roger Hewson(Public Health England), Eva Harris(University of California, Berkeley), Antonio Lanzavecchia(ETH Zurich), Federica Sallusto(Università della Svizzera italiana), Davide Corti(Vir Biotechnology (Switzerland))
Science
July 14, 2016
Cited by 785

Abstract

Zika virus (ZIKV), a mosquito-borne flavivirus with homology to Dengue virus (DENV), has become a public health emergency. By characterizing memory lymphocytes from ZIKV-infected patients, we dissected ZIKV-specific and DENV-cross-reactive immune responses. Antibodies to nonstructural protein 1 (NS1) were largely ZIKV-specific and were used to develop a serological diagnostic tool. In contrast, antibodies against E protein domain I/II (EDI/II) were cross-reactive and, although poorly neutralizing, potently enhanced ZIKV and DENV infection in vitro and lethally enhanced DENV disease in mice. Memory T cells against NS1 or E proteins were poorly cross-reactive, even in donors preexposed to DENV. The most potent neutralizing antibodies were ZIKV-specific and targeted EDIII or quaternary epitopes on infectious virus. An EDIII-specific antibody protected mice from lethal ZIKV infection, illustrating the potential for antibody-based therapy.


Related Papers

No related papers found

Powered by citation graph analysis